Bio-Thera(SH:688177)2021-04-27 16:00Financial Performance - Operating income for the period was ¥60,303,670.69, representing a significant increase of 205.70% year-on-year[10] - Net profit attributable to shareholders of the listed company was -¥109,151,939.71, showing a slight improvement compared to -¥109,473,119.96 in the same period last year[10] - The company reported a net loss of ¥104,906,065.61 for Q1 2021, slightly improved from a loss of ¥114,409,073.32 in Q1 2020[50] - The total comprehensive loss for Q1 2021 was approximately ¥109.05 million, slightly better than the loss of ¥109.51 million in Q1 2020[59] - The basic and diluted earnings per share for Q1 2021 were both ¥-0.26, compared to ¥-0.29 in Q1 2020, showing a slight improvement[59] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,267,499,813.82, a decrease of 5.25% compared to the end of the previous year[10] - The total assets as of March 31, 2021, were 2,267,499,813.82 RMB, down from 2,393,159,821.09 RMB at the end of 2020[32] - The total liabilities as of March 31, 2021, were 371,048,787.27 RMB, compared to 387,556,738.25 RMB at the end of 2020[36] - The company's equity decreased to ¥1,897,520,655.11 from ¥2,006,569,531.37, a decline of 5.4%[46] - Total liabilities amounted to ¥370,981,375.85, down from ¥387,549,626.11, reflecting a reduction of 4.3%[44] Cash Flow - The net cash flow from operating activities was -¥122,893,861.97, an improvement from -¥155,147,320.72 in the same period last year[10] - Cash flow from operating activities for Q1 2021 was -122,851,087.03, an improvement from -155,179,693.28 in Q1 2020[69] - The cash inflow from operating activities in Q1 2021 was approximately ¥82.78 million, compared to ¥37.43 million in Q1 2020, indicating an increase of about 121.5%[63] - The cash outflow for operating activities in Q1 2021 was approximately ¥205.68 million, up from ¥192.58 million in Q1 2020, representing an increase of about 6.8%[63] - The net cash flow from investing activities for Q1 2021 was 56,104,913.68 RMB, a significant recovery from -1,565,392,293.18 RMB in Q1 2020[29] Research and Development - Research and development expenses accounted for 225.62% of operating income, a decrease of 304.57 percentage points compared to the previous year[10] - R&D expenses increased by 30.09% to ¥136,058,889.03 in Q1 2021 from ¥104,586,616.47 in Q1 2020, attributed to advancements in clinical trials and related costs[26] - Research and development expenses for Q1 2021 were approximately ¥137.11 million, up from ¥104.73 million in Q1 2020, reflecting an increase of about 30.8%[57] Shareholder Information - The total number of shareholders at the end of the reporting period was 11,871[17] - The largest shareholder, Guangzhou Qixi Group Co., Ltd., held 38.64% of the shares[17] Tax and Other Charges - The company reported a significant increase in tax and additional charges, which rose by 573.33% to ¥435,786.78 in Q1 2021 from ¥64,721.46 in Q1 2020, due to the expiration of tax incentives[26] - The company’s tax payable increased by 142.62% to ¥2,878,189.58 as of March 31, 2021, compared to ¥1,186,290.69 at the end of 2020, mainly due to increased personal income tax[26] Inventory and Current Assets - The inventory increased to 54,677,647.17 RMB from 45,929,235.72 RMB year-over-year, indicating a growth in stock levels[32] - Current assets totaled approximately $1.47 billion, consistent with prior figures[84] Financial Reporting Changes - The company has implemented new accounting standards for leases effective January 1, 2021, impacting financial reporting[82] - The company adopted new leasing standards effective January 1, 2021, impacting financial statement disclosures[87] - The company will not restate prior year comparative figures under the new leasing standards, only adjusting the current year's financial statement[88]